Vor Biopharma Inc. Other Current Liabilities
Vor Biopharma Inc. (VOR) had Other Current Liabilities of $44.00 thousand as of 2025-03-31, per its 10-Q filed 2025-05-14.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:OtherLiabilitiesCurrent · last filed 2025-05-14
- 2025-03-31: Other Liabilities, Current $44.00K.
- 2024-12-31: Other Liabilities, Current $0.00.
- 2024-09-30: Other Liabilities, Current $13.00K.
- 2024-06-30: Other Liabilities, Current $25.00K.
| Period end | Other Liabilities, Current |
|---|---|
| 2025-03-31 | $44.00K 10-Q · filed 2025-05-14 |
| 2024-12-31 | $0.00 10-Q · filed 2025-05-14 |
| 2024-09-30 | $13.00K 10-Q · filed 2024-11-07 |
| 2024-06-30 | $25.00K 10-Q · filed 2024-08-08 |
| 2024-03-31 | $134.00K 10-Q · filed 2024-05-09 |
| 2023-12-31 | $50.00K 10-K · filed 2025-03-20 |
| 2023-09-30 | $62.00K 10-Q · filed 2023-11-07 |
| 2023-06-30 | $122.00K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $165.00K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $186.00K 10-K · filed 2024-03-20 |
| 2022-09-30 | $233.00K 10-Q · filed 2022-11-10 |
| 2022-06-30 | $279.00K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $351.00K 10-Q · filed 2022-05-12 |
| 2021-12-31 | $434.00K 10-K · filed 2023-03-23 |
| 2021-09-30 | $430.00K 10-Q · filed 2021-11-10 |
| 2021-06-30 | $478.00K 10-Q · filed 2021-08-09 |
| 2021-03-31 | $675.00K 10-Q · filed 2021-05-06 |
| 2020-12-31 | $723.00K 10-K · filed 2022-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |